Magnesia Bisurata Aromatic 40 tablets

In compliance with article 118 "authorization of advertising to the public" of the legislative decree of 24 April 2006, number 219

INDICATIONS

Symptomatic treatment of upper digestive tract pathologies characterized by hyperacidity.

CONTRAINDICATIONS

Hypersensitivity to the active substances or to any of the excipients, listed in paragraph 6.1. Renal failure. Do not administer simultaneously with tetracyclines (see section 4.5). Do not administer other drugs within 1 or 2 hours of using the product (see section 4.5). Administration of the medicine in pediatric age is not recommended.

WARNINGS AND PRECAUTIONS FOR USE

In patients with severe renal insufficiency, plasma magnesium levels tend to increase. In these patients, long exposures to high doses of magnesium can lead to encephalopathy or worsening of dialysis-induced osteomalacia. Generally, caution should be exercised in patients with impaired renal function. In these patients, plasma calcium and magnesium levels should be monitored regularly. Important information about some excipients Magnesia Bisurata Aromatic contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. Magnesia Bisurata Aromatic contains less than 1 mmol (23 mg) sodium per tablet, i.e. essentially 'sodium-free'.

INTERACTIONS

It should be kept in mind that antacids can, through different mechanisms, interfere with the oral administration of other drugs. In particular, the simultaneous administration of tetracyclines can give rise to insoluble complexes, with a reduction in the absorption of these antibiotics. However, it is advisable not to administer other drugs within 1 or 2 hours of using the product. Associations to avoid: tetracyclines: formation of insoluble complexes with reduction in the absorption and activity of these antibiotics. Association not recommended: quinidine: increased plasma levels of quinidine and risk of overdose due to decreased excretion. Associations that require precautions for use: indomethacin, phosphorus, dexamethasone, digitalis, iron salts, nitrofurantoin, lincomycin.

SIDE EFFECTS

Based on the available bibliographic data, there are no known side effects related to the specialty. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.